Prevention & lipidsCohort study
Lipoprotein(a), Inflammation, and Risk of Coronary Artery Disease and Aortic Valve Stenosis
- Prospective cohort study
- population-based
Authors' conclusion
In this primary prevention cohort study, Lp(a)-associated risk for incident CAD was modified by IL-6, with lower associated risk observed in the setting of lower inflammatory biomarker levels.
Study context
- Population
- UK Biobank adults without prevalent coronary artery disease (CAD) or AS who underwent plasma proteomic profiling; primary prevention
- Participants
- 43,512 adults
- Exposure
- Lp ≥125 nmol/L vs <125 nmol/L, by inflammatory biomarker levels
- Lp(a) ≥125 nmol/Ln = 6,975
- Outcome
- Incident CAD
- Follow-up
- Median 13.5 years
Main finding
As reported in the abstract
Incident CAD, by IL-6 quartile (interaction)
Lp(a) ≥125 nmol/L vs Lp(a) <125 nmol/LHazard ratio (95% CI)
IL-6 quartile 4
1.43(1.25–1.63)
IL-6 quartile 1
1.09(0.85–1.38)
Observational data: associations, not effects.
Secondary outcomes
Incident CAD, Lp(a) × neutrophil to lymphocyte ratio (NLR) interaction
- Suggestive but not significant after adjustment for multiple testing
- P for interaction = 0.02
Incident AS · median follow-up 13.6 years
- No inflammatory biomarkers modified Lp(a)-associated risk for AS
Original publication
Lipoprotein(a), Inflammation, and Risk of Coronary Artery Disease and Aortic Valve Stenosis. JAMA Cardiol. Published 1 August 2026. doi:10.1001/jamacardio.2026.1852
Summarised from the published abstract; every number is checked against it